← boardnext 2029-09
RLMD
Relmada Therapeutics, Inc.distress 6/10 · elevated risk$4.88-2%today-38% from 52w high
Oncology 1
Lead: NMIBC
Revenue
pre-revenue
Liquidity
$234M
Runway
5.5 yrs
Shares 1y
+216%
Price & events
+23.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.5%
1D
-10.7%
1W
-28.0%
1M
-32.8%
3M
+25.0%
6M
+578.0%
1Y
+22.2%
2Y
-81.2%
5Y
-85.2%
All
Overview
- Market Cap
- $511.34M
- Volume
- 127.03K
- 52 Week Range
- $0.56 – $7.86
- Total Shares
- 104.89M
- Float Shares
- 7.72M
- Short %
- 10.78%
- % Held by Insiders
- 2.90%
- % Held by Institutions
- 89.66%
- RVOL
- 0.06x
Pipeline stages · 2 programs
NDV-01 (sustained-release gemcitabine-docetaxel)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
NDV01 intravesical controlled release formulation of gemcitabine and docetaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2029-09 Estimated 50% readout ~2029-11-15 | Phase 3 | NDV-01 (sustained-release gemcitabine-docetaxel) | Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Urologic Cancer | — | not yet recruiting |
| 2025-08 | Phase 2 | NDV01 intravesical controlled release formulation of gemcitabine and docetaxel | Non Muscle Invasive Bladder Cancer | 70 | recruiting |
Catalyst news & presentations · 18
- 1st Half 2026Guided 40%trial initiationsecondaryPhase 3NDV-01 · Initiation of Phase 3 trial in high-risk BCG-unresponsive NMIBCSEC 8-K
- 1st Half 2026Guided 40%filing acceptanceFiled (NDA/BLA)NDV-01 · FDA IND clearance for NDV-01SEC 8-K
- YE 2026Guided 40%readoutPhase 3NDV-01 · Initial 3-month data from Phase 3 2L BCG-unresponsive studySEC 8-K
- 1st Half 2026Guided 40%trial initiationsecondaryPhase 2Sepranolone · Initiation of Phase 2 proof-of-concept trial in PWSSEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- Mid-2026trial initiationsecondaryPhase 3NDV-01 · Initiation of Phase 3 RESCUE registrational programSEC 8-K
- 1H 2026trial initiationsecondaryPhase 2sepranolone · Initiation of Phase 2 study for sepranolone in PWSSEC 8-K
- 1H 2026trial initiationsecondaryPhase 3NDV-01 · Initiation of Phase 3 registration-track study for NDV-01SEC 8-K
- 1H 2026filing acceptanceFiled (NDA/BLA)NDV-01 · U.S. IND clearance expectedSEC 8-K
- May 2026conferencedata presentationsecondaryPhase 2NDV-01 · Presentations at AUA2026 on 12-month Phase 2 data and Phase 3 RESCUE program designSEC 8-K
- Q1 2026readoutNDV-01 · 12-month complete response data from Phase 2 trialSEC 8-K
- 2026-01-12fda agreementNDV-01 · FDA alignment on study design, patient populations, primary endpoints for two Phase 3 pathwaysSEC 8-K
- Q4 2025conferencedata presentationsecondaryPhase 2NDV-01 · Nine-month follow-up results from Phase 2 studySEC 8-K
- H2 2025filing acceptanceFiled (NDA/BLA)NDV-01 · FDA interaction and product supply scale upSEC 8-K
- 2025-11-13fda agreementNDV-01 · FDA alignment on Phase 3 program for two NMIBC indicationsSEC 8-K
- 2025-03-24partnershipNDV-01 · Exclusive worldwide license (excluding India, Israel, South Africa) for NDV-01 (gemcitabine/docetaxel) with up to $200M in milestones and 3% royaltiesSEC 8-K
- 2025-02-03partnershipSepranolone · Acquired Sepranolone from Asarina Pharma AB for €3,000,000 for Tourette syndrome and other compulsive disorders.SEC 8-K
- 2024-12-09trial discontinuedREL-P11 · Continuing Phase 1 study of REL-P11 for metabolic disease.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $13 (+160% upside) · 6 analysts
- 2026-06-18HC Wainwright & Co.Buy
- 2026-03-24Piper SandlerOverweight
- 2026-03-20MizuhoOutperform
- 2026-03-02LUCID CAPITAL MARKETSBuy
- 2026-01-23Leerink PartnersMarket Perform → Outperform
- 2025-12-22JefferiesBuy
Competitors — NMIBC
- IBRXImmunityBio, Inc.$7.8B · D5
- CGONCG Oncology, Inc.$6.1B · D1
- URGNUroGen Pharma Ltd.$2.0B · D5
- TYRATyra Biosciences, Inc.$1.8B · D3
- AURAAura Biosciences, Inc.$722M · D6
- TARAProtara Therapeutics, Inc.$225M · D3
- ENGNenGene Therapeutics Inc.$122M · D1
- ENGNWenGene Therapeutics Inc.$24M · D5
- SBFMSunshine Biopharma Inc.$9M · D3
- TLTFF— · D4
Recent news
- 2026-07-16Relmada Therapeutics to announce Q2 2026 financial results - scanx.trade
- 2026-07-16Relmada Sets Aug. 6 Call to Discuss Second-Quarter Results - Stock Titan
- 2026-07-16Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 - GlobeNewswire
- 2026-07-11RELMADA THERAPEUTICS INC (RLMD) Stock Chart - ChartMill
- 2026-07-10Relmada Therapeutics (RLMD) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
- 2026-06-29Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to Russell 2500 Growth Benchmark - marketscreener.com
- 2026-06-29Relmada Therapeutics Joins Russell 2000, Russell 3000 Indexes - marketscreener.com
- 2026-06-28Relmada Therapeutics, Inc.(NasdaqCM:RLMD) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.